Zydus has received regulatory approval from the Drug Controller General of India (DCGI) to market and manufacture semaglutide to treat type 2 diabetes and obesity.
Zydus plans obesity jab launch in a novel pen device
Zydus has received regulatory approval from the Drug Controller General of India (DCGI) to market and manufacture semaglutide to treat type 2 diabetes and obesity.
